The effect of intramuscular testosterone enanthate treatment on stretched penile length in prepubertal boys with hypospadias

Tomohiro Ishii, Mie Hayashi, Ayuko Suwanai, Naoko Amano, Tomonobu Hasegawa

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

OBJECTIVES To define the responses of stretched penile length (PL) to intramuscular testosterone enanthate (TE) treatment in prepubertal boys with hypospadias. METHODS We examined 17 Japanese boys with hypospadias at 1.4 ± 1.3 (mean ± SD) years of age. Their PLs were 2.79 ± 0.37 cm and -1.16 ± 0.88 SD of the mean. The etiology of hypospadias included sex chromosome disorders of sex development in 5, mastermind-like domain-containing 1 deficiency in 1, and unknown cause in the others. No mutation was identified in the SRD5A2 or AR gene. All the boys received as many as three intramuscular injections of TE 25 mg every 4 weeks (one injection in 3 boys, two in 5, and three in 9). RESULTS The TE treatment significantly increased PL by 1.01 ± 0.50 cm and 2.27 ± 0.99 SD (cm, P = .0002; SD, P = .0002). Age, body surface area (BSA), and PL before the treatment did not significantly correlate with the effect of TE treatment on PL. The effect of TE treatment on PL at the first injection in Japanese boys with hypospadias (0.35 ± 0.20 cm and 0.91 ± 0.62 SD) was significantly less than that in micropenis at 2.6 - 3.1 years of age (0.64 ± 0.26 cm and 1.37 - 0.68 SD) (cm, P = .0008; SD, P = .02). CONCLUSIONS These data indicate that (1) the intramuscular TE treatment significantly increases PL for hypospadias in prepubertal boys, with no demonstrable SRD5A2 or AR mutation; (2) age, BSA, and PL before the treatment are not significantly contributing factors to the effect of TE treatment; and (3) the effect of TE treatment for hypospadias is significantly less than that for micropenis.

Original languageEnglish
Pages (from-to)97-100
Number of pages4
JournalUrology
Volume76
Issue number1
DOIs
Publication statusPublished - 2010 Jul

Fingerprint

Hypospadias
Therapeutics
Body Surface Area
Sex Chromosome Disorders of Sex Development
testosterone enanthate
Mutation
Injections
Intramuscular Injections

ASJC Scopus subject areas

  • Urology

Cite this

The effect of intramuscular testosterone enanthate treatment on stretched penile length in prepubertal boys with hypospadias. / Ishii, Tomohiro; Hayashi, Mie; Suwanai, Ayuko; Amano, Naoko; Hasegawa, Tomonobu.

In: Urology, Vol. 76, No. 1, 07.2010, p. 97-100.

Research output: Contribution to journalArticle

@article{8addaa116de84955af3f723f9a1275d9,
title = "The effect of intramuscular testosterone enanthate treatment on stretched penile length in prepubertal boys with hypospadias",
abstract = "OBJECTIVES To define the responses of stretched penile length (PL) to intramuscular testosterone enanthate (TE) treatment in prepubertal boys with hypospadias. METHODS We examined 17 Japanese boys with hypospadias at 1.4 ± 1.3 (mean ± SD) years of age. Their PLs were 2.79 ± 0.37 cm and -1.16 ± 0.88 SD of the mean. The etiology of hypospadias included sex chromosome disorders of sex development in 5, mastermind-like domain-containing 1 deficiency in 1, and unknown cause in the others. No mutation was identified in the SRD5A2 or AR gene. All the boys received as many as three intramuscular injections of TE 25 mg every 4 weeks (one injection in 3 boys, two in 5, and three in 9). RESULTS The TE treatment significantly increased PL by 1.01 ± 0.50 cm and 2.27 ± 0.99 SD (cm, P = .0002; SD, P = .0002). Age, body surface area (BSA), and PL before the treatment did not significantly correlate with the effect of TE treatment on PL. The effect of TE treatment on PL at the first injection in Japanese boys with hypospadias (0.35 ± 0.20 cm and 0.91 ± 0.62 SD) was significantly less than that in micropenis at 2.6 - 3.1 years of age (0.64 ± 0.26 cm and 1.37 - 0.68 SD) (cm, P = .0008; SD, P = .02). CONCLUSIONS These data indicate that (1) the intramuscular TE treatment significantly increases PL for hypospadias in prepubertal boys, with no demonstrable SRD5A2 or AR mutation; (2) age, BSA, and PL before the treatment are not significantly contributing factors to the effect of TE treatment; and (3) the effect of TE treatment for hypospadias is significantly less than that for micropenis.",
author = "Tomohiro Ishii and Mie Hayashi and Ayuko Suwanai and Naoko Amano and Tomonobu Hasegawa",
year = "2010",
month = "7",
doi = "10.1016/j.urology.2009.12.065",
language = "English",
volume = "76",
pages = "97--100",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - The effect of intramuscular testosterone enanthate treatment on stretched penile length in prepubertal boys with hypospadias

AU - Ishii, Tomohiro

AU - Hayashi, Mie

AU - Suwanai, Ayuko

AU - Amano, Naoko

AU - Hasegawa, Tomonobu

PY - 2010/7

Y1 - 2010/7

N2 - OBJECTIVES To define the responses of stretched penile length (PL) to intramuscular testosterone enanthate (TE) treatment in prepubertal boys with hypospadias. METHODS We examined 17 Japanese boys with hypospadias at 1.4 ± 1.3 (mean ± SD) years of age. Their PLs were 2.79 ± 0.37 cm and -1.16 ± 0.88 SD of the mean. The etiology of hypospadias included sex chromosome disorders of sex development in 5, mastermind-like domain-containing 1 deficiency in 1, and unknown cause in the others. No mutation was identified in the SRD5A2 or AR gene. All the boys received as many as three intramuscular injections of TE 25 mg every 4 weeks (one injection in 3 boys, two in 5, and three in 9). RESULTS The TE treatment significantly increased PL by 1.01 ± 0.50 cm and 2.27 ± 0.99 SD (cm, P = .0002; SD, P = .0002). Age, body surface area (BSA), and PL before the treatment did not significantly correlate with the effect of TE treatment on PL. The effect of TE treatment on PL at the first injection in Japanese boys with hypospadias (0.35 ± 0.20 cm and 0.91 ± 0.62 SD) was significantly less than that in micropenis at 2.6 - 3.1 years of age (0.64 ± 0.26 cm and 1.37 - 0.68 SD) (cm, P = .0008; SD, P = .02). CONCLUSIONS These data indicate that (1) the intramuscular TE treatment significantly increases PL for hypospadias in prepubertal boys, with no demonstrable SRD5A2 or AR mutation; (2) age, BSA, and PL before the treatment are not significantly contributing factors to the effect of TE treatment; and (3) the effect of TE treatment for hypospadias is significantly less than that for micropenis.

AB - OBJECTIVES To define the responses of stretched penile length (PL) to intramuscular testosterone enanthate (TE) treatment in prepubertal boys with hypospadias. METHODS We examined 17 Japanese boys with hypospadias at 1.4 ± 1.3 (mean ± SD) years of age. Their PLs were 2.79 ± 0.37 cm and -1.16 ± 0.88 SD of the mean. The etiology of hypospadias included sex chromosome disorders of sex development in 5, mastermind-like domain-containing 1 deficiency in 1, and unknown cause in the others. No mutation was identified in the SRD5A2 or AR gene. All the boys received as many as three intramuscular injections of TE 25 mg every 4 weeks (one injection in 3 boys, two in 5, and three in 9). RESULTS The TE treatment significantly increased PL by 1.01 ± 0.50 cm and 2.27 ± 0.99 SD (cm, P = .0002; SD, P = .0002). Age, body surface area (BSA), and PL before the treatment did not significantly correlate with the effect of TE treatment on PL. The effect of TE treatment on PL at the first injection in Japanese boys with hypospadias (0.35 ± 0.20 cm and 0.91 ± 0.62 SD) was significantly less than that in micropenis at 2.6 - 3.1 years of age (0.64 ± 0.26 cm and 1.37 - 0.68 SD) (cm, P = .0008; SD, P = .02). CONCLUSIONS These data indicate that (1) the intramuscular TE treatment significantly increases PL for hypospadias in prepubertal boys, with no demonstrable SRD5A2 or AR mutation; (2) age, BSA, and PL before the treatment are not significantly contributing factors to the effect of TE treatment; and (3) the effect of TE treatment for hypospadias is significantly less than that for micropenis.

UR - http://www.scopus.com/inward/record.url?scp=77955903683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955903683&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2009.12.065

DO - 10.1016/j.urology.2009.12.065

M3 - Article

C2 - 20350750

AN - SCOPUS:77955903683

VL - 76

SP - 97

EP - 100

JO - Urology

JF - Urology

SN - 0090-4295

IS - 1

ER -